Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis

a meta-analysis of randomized placebo-controlled trials

E. M. Bartels, H. Bliddal, P. K. Schøndorff, Roy D Altman, W. Zhang, R. Christensen

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: To estimate the efficacy and safety of diacerein as a pain-reducing agent in the treatment of osteoarthritis (OA), using meta-analysis of published randomized placebo-controlled trials (RCTs). Methods: Systematic searches of the bibliographic databases Medline, Embase, Cinahl, Chemical Abstracts, Cochrane and Web of Science for RCTs concerning diacerein treatment of OA. Inclusion criteria: explicit statement about randomization to either diacerein or placebo, and co-primary outcomes being reduction in pain and improvement in function. Efficacy effect size (ES) was estimated using Hedges's standardized mean difference. Safety was measured via the risk ratio (RR) of patients having at least one episode of diarrhoea, or withdrawal due to adverse events. Trials were combined by using random-effects meta-analysis. Consistency was evaluated via the I-squared index. Results: Six trials (seven sub-studies; 1533 patients) contributed to the meta-analysis, revealing a large degree of inconsistency among the trials (I 2 = 56%) in regard to pain reduction: the combined ES was -0.24 [95% confidence intervals (CI): -0.39 to -0.08, P = 0.003], favouring diacerein. The statistically significant improvement in function (P = 0.01) was based on a small amount of heterogeneity (I 2 = 11%), but presented a questionable clinical effect size (ES = -0.14). Risk of publication bias could not be excluded, and trials with duration of more than 6 months did not favour diacerein. There was an increased risk of diarrhoea with diacerein (RR = 3.51 [2.55-4.83], P <0.0001), and some withdrawal from therapy following adverse events (RR = 1.58 [1.05-2.36], P = 0.03). Conclusions: Diacerein may be an alternative therapy for OA for patients who cannot take paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) because of adverse effects or lack of benefit. However, it is associated with increased risk of diarrhoea, and the symptomatic benefit after 6 months remains unknown.

Original languageEnglish (US)
Pages (from-to)289-296
Number of pages8
JournalOsteoarthritis and Cartilage
Volume18
Issue number3
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

diacetylrhein
Osteoarthritis
Meta-Analysis
Randomized Controlled Trials
Placebos
Safety
Diarrhea
Odds Ratio
Pain
Therapeutics
Bibliographic Databases
Publication Bias
Reducing agents
Reducing Agents
Acetaminophen
Complementary Therapies
Random Allocation

ASJC Scopus subject areas

  • Biomedical Engineering
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis : a meta-analysis of randomized placebo-controlled trials. / Bartels, E. M.; Bliddal, H.; Schøndorff, P. K.; Altman, Roy D; Zhang, W.; Christensen, R.

In: Osteoarthritis and Cartilage, Vol. 18, No. 3, 03.2010, p. 289-296.

Research output: Contribution to journalArticle

Bartels, E. M. ; Bliddal, H. ; Schøndorff, P. K. ; Altman, Roy D ; Zhang, W. ; Christensen, R. / Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis : a meta-analysis of randomized placebo-controlled trials. In: Osteoarthritis and Cartilage. 2010 ; Vol. 18, No. 3. pp. 289-296.
@article{e1552acc67444d9f9697cf14d70b8d63,
title = "Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials",
abstract = "Objective: To estimate the efficacy and safety of diacerein as a pain-reducing agent in the treatment of osteoarthritis (OA), using meta-analysis of published randomized placebo-controlled trials (RCTs). Methods: Systematic searches of the bibliographic databases Medline, Embase, Cinahl, Chemical Abstracts, Cochrane and Web of Science for RCTs concerning diacerein treatment of OA. Inclusion criteria: explicit statement about randomization to either diacerein or placebo, and co-primary outcomes being reduction in pain and improvement in function. Efficacy effect size (ES) was estimated using Hedges's standardized mean difference. Safety was measured via the risk ratio (RR) of patients having at least one episode of diarrhoea, or withdrawal due to adverse events. Trials were combined by using random-effects meta-analysis. Consistency was evaluated via the I-squared index. Results: Six trials (seven sub-studies; 1533 patients) contributed to the meta-analysis, revealing a large degree of inconsistency among the trials (I 2 = 56{\%}) in regard to pain reduction: the combined ES was -0.24 [95{\%} confidence intervals (CI): -0.39 to -0.08, P = 0.003], favouring diacerein. The statistically significant improvement in function (P = 0.01) was based on a small amount of heterogeneity (I 2 = 11{\%}), but presented a questionable clinical effect size (ES = -0.14). Risk of publication bias could not be excluded, and trials with duration of more than 6 months did not favour diacerein. There was an increased risk of diarrhoea with diacerein (RR = 3.51 [2.55-4.83], P <0.0001), and some withdrawal from therapy following adverse events (RR = 1.58 [1.05-2.36], P = 0.03). Conclusions: Diacerein may be an alternative therapy for OA for patients who cannot take paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) because of adverse effects or lack of benefit. However, it is associated with increased risk of diarrhoea, and the symptomatic benefit after 6 months remains unknown.",
author = "Bartels, {E. M.} and H. Bliddal and Sch{\o}ndorff, {P. K.} and Altman, {Roy D} and W. Zhang and R. Christensen",
year = "2010",
month = "3",
doi = "10.1016/j.joca.2009.10.006",
language = "English (US)",
volume = "18",
pages = "289--296",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis

T2 - a meta-analysis of randomized placebo-controlled trials

AU - Bartels, E. M.

AU - Bliddal, H.

AU - Schøndorff, P. K.

AU - Altman, Roy D

AU - Zhang, W.

AU - Christensen, R.

PY - 2010/3

Y1 - 2010/3

N2 - Objective: To estimate the efficacy and safety of diacerein as a pain-reducing agent in the treatment of osteoarthritis (OA), using meta-analysis of published randomized placebo-controlled trials (RCTs). Methods: Systematic searches of the bibliographic databases Medline, Embase, Cinahl, Chemical Abstracts, Cochrane and Web of Science for RCTs concerning diacerein treatment of OA. Inclusion criteria: explicit statement about randomization to either diacerein or placebo, and co-primary outcomes being reduction in pain and improvement in function. Efficacy effect size (ES) was estimated using Hedges's standardized mean difference. Safety was measured via the risk ratio (RR) of patients having at least one episode of diarrhoea, or withdrawal due to adverse events. Trials were combined by using random-effects meta-analysis. Consistency was evaluated via the I-squared index. Results: Six trials (seven sub-studies; 1533 patients) contributed to the meta-analysis, revealing a large degree of inconsistency among the trials (I 2 = 56%) in regard to pain reduction: the combined ES was -0.24 [95% confidence intervals (CI): -0.39 to -0.08, P = 0.003], favouring diacerein. The statistically significant improvement in function (P = 0.01) was based on a small amount of heterogeneity (I 2 = 11%), but presented a questionable clinical effect size (ES = -0.14). Risk of publication bias could not be excluded, and trials with duration of more than 6 months did not favour diacerein. There was an increased risk of diarrhoea with diacerein (RR = 3.51 [2.55-4.83], P <0.0001), and some withdrawal from therapy following adverse events (RR = 1.58 [1.05-2.36], P = 0.03). Conclusions: Diacerein may be an alternative therapy for OA for patients who cannot take paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) because of adverse effects or lack of benefit. However, it is associated with increased risk of diarrhoea, and the symptomatic benefit after 6 months remains unknown.

AB - Objective: To estimate the efficacy and safety of diacerein as a pain-reducing agent in the treatment of osteoarthritis (OA), using meta-analysis of published randomized placebo-controlled trials (RCTs). Methods: Systematic searches of the bibliographic databases Medline, Embase, Cinahl, Chemical Abstracts, Cochrane and Web of Science for RCTs concerning diacerein treatment of OA. Inclusion criteria: explicit statement about randomization to either diacerein or placebo, and co-primary outcomes being reduction in pain and improvement in function. Efficacy effect size (ES) was estimated using Hedges's standardized mean difference. Safety was measured via the risk ratio (RR) of patients having at least one episode of diarrhoea, or withdrawal due to adverse events. Trials were combined by using random-effects meta-analysis. Consistency was evaluated via the I-squared index. Results: Six trials (seven sub-studies; 1533 patients) contributed to the meta-analysis, revealing a large degree of inconsistency among the trials (I 2 = 56%) in regard to pain reduction: the combined ES was -0.24 [95% confidence intervals (CI): -0.39 to -0.08, P = 0.003], favouring diacerein. The statistically significant improvement in function (P = 0.01) was based on a small amount of heterogeneity (I 2 = 11%), but presented a questionable clinical effect size (ES = -0.14). Risk of publication bias could not be excluded, and trials with duration of more than 6 months did not favour diacerein. There was an increased risk of diarrhoea with diacerein (RR = 3.51 [2.55-4.83], P <0.0001), and some withdrawal from therapy following adverse events (RR = 1.58 [1.05-2.36], P = 0.03). Conclusions: Diacerein may be an alternative therapy for OA for patients who cannot take paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) because of adverse effects or lack of benefit. However, it is associated with increased risk of diarrhoea, and the symptomatic benefit after 6 months remains unknown.

UR - http://www.scopus.com/inward/record.url?scp=76549112463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549112463&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2009.10.006

DO - 10.1016/j.joca.2009.10.006

M3 - Article

VL - 18

SP - 289

EP - 296

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - 3

ER -